J&J's Janssen Pharmaceutica to Develop MDx Assays for Biocartis' Integrated NAT Platform
January 13, 2011
J&J's Janssen Pharmaceutica to Develop MDx Assays for Biocartis' Integrated NAT Platform
Janssen becomes the third assay content provider for Biocartis' integrated "sample-to-answer" nucleic acid testing platform as the company drives toward a full commercial launch in the second half of 2012.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- BioMérieux Buys Argene to Bolster Test Menu for Biocartis MDx Platform
July 21, 2011 / PCR Insider - Debiopharm Invests in Diagnoplex to Push Colon Cancer MDx Through Clinical Trials
January 20, 2011 / PCR Insider - Janssen to Develop Assays on Biocartis MDx Platform
January 10, 2011 / GenomeWeb Daily News - IP Watch: Biocartis, Biosearch, Hologic's Gen-Probe, Luminex, Rubicon, Others Win US Patents
May 15, 2013 / PCR Insider - Lumora-FIND Malaria Screening Test May be Tip of Iceberg in MDx Development Partnership
April 18, 2013 / PCR Insider